Xenetic Biosciences, Inc. — Q1 2022 Form 10-Q
Period: Three months ended March 31, 2022; unaudited. Xenetic is a clinical-stage biopharmaceutical company developing immune-oncology technologies. Its programs include the XCART personalized CAR T platform and, following an April 2022 licensing transaction, a DNase oncology platform. PolyXen generates royalty revenue. The company has no approved products.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Revenue (royalties) | $389,000 | $191,000 |
| Research and development expense | $1.101 million | $630,000 |
| General and administrative expense | $907,000 | $931,000 |
| Operating loss | $1.620 million | $1.369 million |
| Net loss | $1.594 million | $1.346 million |
| Basic and diluted loss per share | $0.12 | $0.15 |
| Cash and cash equivalents | $16.156 million | $18.244 million at Dec. 31, 2021 |
| Working capital | $15.8 million | $17.3 million at Dec. 31, 2021 |
| Current and total liabilities | $1.063 million | $1.421 million at Dec. 31, 2021 |
| Operating cash used | $2.088 million | $1.519 million |
Royalty revenue was the company’s only reported revenue. No gross margin was reported. There were no investing or financing cash flows in either quarter. The balance sheet reports no long-term liabilities; the filing does not identify outstanding corporate debt. Cash declined by $2.088 million during Q1. Management said available resources were expected to fund operations into Q2 2023.
Changes and management commentary
- Revenue rose 103.4%, reflecting higher Takeda-related royalties as its sublicensee continued a product launch.
- R&D expense increased 74.9%, mainly from greater XCART preclinical development spending and consulting costs related to the DNase licensing. G&A expense decreased 2.5%.
- Net loss increased 18.4%. Loss per share improved from $0.15 to $0.12, while weighted-average common shares increased from 8.75 million to 13.44 million.
- Management expects continuing losses and says additional long-term capital may be needed. The filing states that substantial losses raise substantial doubt about the company’s ability to continue as a going concern, while management believes it can access financing and has sufficient resources into Q2 2023.
Post-quarter transaction, risks, and contingencies
- On April 26, 2022, Xenetic entered two exclusive agreements with CLS Therapeutics for DNase oncology applications: one covering DNase products for cancer and another covering DNase used with CAR T therapies. Xenetic will lead development and commercialization in the specified U.S. and European markets.
- Under the sublicense agreement, Xenetic issued 375,000 common shares and may owe up to $13 million in clinical and regulatory milestone payments, plus royalties and a share of certain sublicense consideration. The agreement also provides for up to 950,000 additional shares tied to regulatory milestones.
- Under the separate license agreement, Xenetic paid CLS $500,000 and issued 500,000 shares; it may owe up to $13 million in milestone payments, plus royalties and a share of certain sublicense consideration. These obligations are contingent on specified events or sales.
- A $0.4 million related-party loan receivable from Pharmsynthez was classified as long-term after the borrower requested an extension of principal repayments to September 2022. Final extension terms were still under negotiation. Xenetic cited Russia-Ukraine conflict-related uncertainty but judged the collateral adequate.
- Key risks include development, clinical, regulatory, manufacturing, commercialization and financing uncertainty; dependence on the DNase platform’s success; reliance on collaborators; and possible effects of COVID-19 and geopolitical or market conditions. The company reported no material legal proceedings and no material changes to previously disclosed risk factors other than those described in the filing.
Important facts for investors to verify
- Whether Xenetic can fund operations beyond management’s stated Q2 2023 runway, particularly as it advances the CLS-licensed programs.
- The development plans, required funding, milestones, and potential dilution associated with the CLS agreements.
- Progress and spending on XCART and DNase, and whether collaborations or financing can support development.
- Collection timing and final extension terms for the Pharmsynthez loan receivable.
- Future Takeda royalty reports and revenue, which depend on sales of covered products.